CD274 and melanoma: Despite these promising results, in breast cancer, checkpoint inhibitors have so far not shown as clear and consistent efficacy as in other types of cancer, such as melanoma and non-small cell lung cancer, since not all PD-L1-positive TNBC patients respond to immunotherapy; therefore, identification of reliable biomarkers to predict response remains an active area of research [52].